FUL.L Regulatory News (FUL)

6 Jan 2005 07:00

Fulcrum Pharma PLC06 January 2005 For immediate release 6 January 2005 Fulcrum Pharma plc ("Fulcrum" or "the Company") Board Appointment Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcingservices company, is pleased to announce the appointment of Dr Bruce McCreedy,the Chief Executive Officer of Fulcrum's US subsidiary, to the Company's Board. His appointment to the Board underlines the growing importance to Fulcrum of theUS market, where the Company is experiencing its fastest growth and is focussinginvestment. Dr McCreedy joined Fulcrum in June 2002 as Chief Executive Officer of FulcrumPharmaceutical Developments, Inc, Fulcrum's US subsidiary based in ResearchTriangle Park, North Carolina. Under Dr McCreedy's capable stewardship thesubsidiary, which is a key element in Fulcrum's growth strategy, has performedahead of target in its second year of operations. Dr McCreedy, who holds a PhD from Wake University School of Medicine, NorthCarolina, has more than seventeen years' experience of drug development,executive management and business operations. This includes experience in bothpublic and private companies, licensing, M&A plus public and private financings. Prior to joining Fulcrum he held positions including Associate Vice President ofInfectious Diseases and Clinical Trials with Roche Biomedical Laboratories (nowLaboratory Corporation of America), Vice President of Clinical Virology andDiagnostics with Triangle Pharmaceuticals, and Chief Executive Officer ofTherapyEdge, Inc., a company he co-founded as a spin-off from TrianglePharmaceuticals. Dr McCreedy joined Fulcrum's Board on the 1 January 2005. Professor Sir Charles George, Chairman of Fulcrum Pharma, said: "I am delightedto welcome Dr McCreedy to the Company's Board. His appointment will reinforceFulcrum's progress in the US, the world's largest healthcare market and onewhere our services are proving attractive to pharmaceutical and biotechnologycompanies." For further information, please contact: Fulcrum Pharma PLC Tel: 0870 710 7152Jon Court, CEO Buchanan Communications Tel: 020 7466 5000Mary-Jane Johnson Notes to Editors: About Fulcrum Pharma Fulcrum Pharma plc is an independent, drug development company that is the firstto offer global virtual drug development and strategic outsourcing services tothe pharmaceutical industry. The Company has expertise in the design, executionand delivery of drug development programmes and relies on state of the artinformation technology and infrastructure in the supply of its services. Through Fulcrum's services to its clients, the Directors believe that there isthe capacity to deliver products faster and more efficiently to the globalpharmaceutical market. Fulcrum does this by using its skills in the design ofdrug programmes that deliver the necessary information for decision-making andproduct registration. In so doing, Fulcrum works closely with its clients tomeet their strategic R&D goals. Fulcrum Pharma is listed on the Alternative Investment Market of the LondonStock Exchange having successfully floated in March 2000. This information is provided by RNS The company news service from the London Stock Exchange